Teleflex, a Pennsylvania-based healthcare supplies and services provider, has agreed to acquire hemostatic devices manufacturer Z-Medica, in a deal worth up to $525 million. Based in Connecticut, Z-Medica is a portfolio company of Linden Capital Partners. The company is engaged in developing and commercializing hemorrhage control products. Its three main hemostatic device brands are QuikClot, […]
Continue reading …Exact Sciences, a US molecular diagnostics company, has agreed to acquire Thrive Earlier Detection in a cash cum stock deal worth up to $2.15 billion, in a move to become a leading player in blood-based, multi-cancer screening. Based in Cambridge and Baltimore, Thrive Earlier Detection is a healthcare company focused on incorporating earlier cancer detection […]
Continue reading …Gilead Sciences has wrapped up its previously announced $21 billion acquisition of New Jersey-based biopharma company Immunomedics. With the completion of the deal, Immunomedics has now become a fully-owned subsidiary of Gilead Sciences. The common stock of Immunomedics will be delisted from the Nasdaq Global Market. Immunomedics, which has been acquired for $88 per share […]
Continue reading …Remdesivir FDA approval : Gilead Sciences, a California-based biopharma company, has bagged approval from the US Food and Drug Administration (FDA) for its antiviral drug Veklury (remdesivir) for Covid-19 treatment in patients requiring hospitalization. This makes remdesivir the first approved treatment for coronavirus in the US. Remdesivir FDA approved indication : Veklury has been approved […]
Continue reading …VelosBio, a San Diego-based biopharma company, said that it has dosed the first patient in a phase 2 clinical trial of its investigational antibody-drug conjugate (ADC) VLS-101 in patients having solid tumors. VLS-101, which is the company’s lead product candidate, targets a cell-surface protein called ROR1. Expressed during embryofetal development, ROR1 is however not seen […]
Continue reading …Endo International has agreed to acquire BioSpecifics Technologies, a New York-based commercial-stage biopharma company, for $88.5 per share, or an estimated enterprise value of around $658 million. The Irish pharma company and BioSpecifics Technologies have been in a strategic partnership since 2004. BioSpecifics Technologies had developing a form of injectable collagenase clostridium histolyticum (CCH), which […]
Continue reading …Bracco Diagnostics, the US subsidiary of Italian diagnostic imaging company Bracco Imaging, has secured approval from the US Food and Drug Administration (FDA) for its new CardioGen-82 infusion system. According to Bracco Diagnostics, CardioGen-82 infusion system is used for improving automation, efficiency, and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). CARDIOGEN-82 […]
Continue reading …Lilly acquisition of Disarm Therapeutics : Eli Lilly and Company (Lilly) has agreed to acquire Disarm Therapeutics, a biotech company based in Cambridge, Massachusetts, which is focused on developing a new class of disease-modifying treatments for patients with axonal degeneration. As per the terms of the deal, Lilly will pay an upfront payment of $135 […]
Continue reading …Inmazeb FDA approval : Regeneron Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its antibody cocktail Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of Zaire ebolavirus (Ebola virus). Formerly known as REGN-EB3, Inmazeb is now the first drug regimen to get FDA approval for Ebola treatment, covering adult and […]
Continue reading …AstraZeneca said that AZD7442, which is being developed for the prevention and treatment of Covid-19, will move into two phase 3 clinical trials. AZD7442 is a combination of a couple of monoclonal antibodies (mAbs) extracted from convalescent patients with SARS-CoV-2 infection. It will be assessed in more than 6,000 participants at sites in and outside […]
Continue reading …